Publication Ethics
Publication ethics and publication malpractice statement of Creative Pharma Assent (CPA) is mainly based on the Code of Conduct and Best-Practice Guidelines for Journal Editors (Committee on Publication Ethics, 2011).
Editors' responsibilities
Publication decisions
The editor is responsible for deciding which of the papers submitted to the journal will be published. The editor will evaluate manuscripts without regard to the authors' race, gender, sexual orientation, religious belief, ethnic origin, citizenship, or political philosophy. The decision will be based on the paper’s importance, originality and clarity, and the study’s validity and its relevance to the journal's scope. Current legal requirements regarding libel, copyright infringement, and plagiarism should also be considered.
Confidentiality
The editor and any editorial staff must not disclose any information about a submitted manuscript to anyone other than the corresponding author, reviewers, potential reviewers, other editorial advisers, and the publisher, as appropriate.
Disclosure and conflicts of interest
Unpublished materials disclosed in a submitted paper will not be used by the editor or the members of the editorial board for their own research purposes without the author's explicit written consent.
Reviewers' responsibilities
Contribution to editorial decisions
The peer-reviewing process assists the editor and the editorial board in making editorial decisions and may also serve the author in improving the paper
Promptness
Any selected referee who feels unqualified to review the research reported in a manuscript or knows that its prompt review will be impossible should notify the editor and withdraw from the review process.
Confidentiality
Any manuscripts received for review must be treated as confidential documents. They must not be disclosed to or discussed with others except as authorized by the editor.
Standards of objectivity
Reviews should be conducted objectively. Personal criticism of the author is inappropriate. Referees should express their views clearly with supporting arguments.
Funding sources
Reviewers should identify cases in which relevant published work referred to in the paper has not been cited in the reference section. They should point out whether observations or arguments derived from other publications are accompanied by the respective source. Reviewers will notify the editor of any substantial similarity or overlap between the manuscript under consideration and any other published paper of which they have personal knowledge.
Disclosure and conflict of interest
Privileged information or ideas obtained through peer review must be kept confidential and not used for personal advantage. Reviewers should not consider manuscripts in which they have conflicts of interest resulting from competitive, collaborative, or other relationships or connections with any of the authors, companies, or institutions associated with the papers.
Authors' responsibilities
Reporting standards
Authors of original research reports should present an accurate account of the work performed as well as an objective discussion of its significance. Underlying data should be represented accurately in the paper. A paper should contain sufficient detail and references to permit others to replicate the work. Fraudulent or knowingly inaccurate statements constitute unethical behavior and are unacceptable.
Originality, plagiarism and acknowledgement of sources
Authors will submit only entirely original works, and will appropriately cite or quote the work and/or words of others. Publications that have been influential in determining the nature of the reported work should also be cited.
Multiple, redundant or concurrent publication
In general, papers describing essentially the same research should not be published in more than one journal. Submitting the same paper to more than one journal constitutes unethical publishing behavior and is unacceptable.
Manuscripts which have been published as copyrighted material elsewhere cannot be submitted. In addition, manuscripts under review by the journal should not be resubmitted to copyrighted publications. However, by submitting a manuscript, the author(s) retain the rights to the published material.
Authors and co – authors of the paper
Authorship should be limited to those who have made a significant contribution to the conception, design, execution, or interpretation of the reported study. All those who have made significant contributions should be listed as co-authors.
The corresponding author ensures that all contributing co-authors and no uninvolved persons are included in the author list. The corresponding author will also verify that all co-authors have approved the final version of the paper and have agreed to its submission for publication.
Disclosure and conflicts of interest
All authors should include a statement disclosing any financial or other substantive conflicts of interest that may be construed to influence the results or interpretation of their manuscript. All sources of financial support for the project should be disclosed.
Fundamental errors in published works
When an author discovers a significant error or inaccuracy in his/her own published work, it is the author’s obligation to promptly notify the journal editor or publisher and to cooperate with the editor to retract or correct the paper in form of an erratum.
Governing Body
Creative Pharma Assent is a dynamic organization dedicated to fostering innovation and advancing research in the pharmaceutical sciences. It manages several initiatives, including the Journal of Applied Pharmaceutical Research (JOAPR), aimed at promoting scientific knowledge and breakthroughs in the pharmaceutical field.
The governing body of Creative Pharma Assent consists of a team of seasoned professionals, including experts in pharmaceutical sciences, regulatory affairs, research development, and business management. Their collective vision is to ensure that the organization upholds the highest standards of excellence, both in scientific contributions and industry leadership.
Key functions of the governing body include:
-
Strategic Leadership: Setting the long-term vision and mission of Creative Pharma Assent to align with global pharmaceutical research trends.
-
Operational Oversight: Managing the day-to-day operations and ensuring that all projects, including the Journal of Applied Pharmaceutical Research, run efficiently and meet established goals.
-
Ethical and Regulatory Compliance: Ensuring that the organization's initiatives comply with international ethical standards and regulatory frameworks.
By blending academic rigor with practical industry insights, the governing body of Creative Pharma Assent plays a pivotal role in supporting scientific advancements and maintaining the organization's influence in the global pharmaceutical landscape.
Allegations of Research Misconduct
Research misconduct means fabrication, falsification, citation manipulation, or plagiarism in producing, performing, or reviewing research and writing an article by authors, or in reporting research results. When authors are found to have been involved with research misconduct or other serious irregularities involving articles that have been published in scientific journals, Editors have a responsibility to ensure the accuracy and integrity of the scientific record.
In cases of suspected misconduct, the Editors and Editorial Board will use the best practices of COPE to assist them to resolve the complaint and address the misconduct fairly. This will include an investigation of the allegation by the Editors. A submitted manuscript that is found to contain such misconduct will be rejected. In cases where a published paper is found to contain such misconduct, a retraction can be published and will be linked to the original article.
The first step involves determining the validity of the allegation and an assessment of whether the allegation is consistent with the definition of research misconduct. This initial step also involves determining whether the individuals alleging misconduct have relevant conflicts of interest.
If scientific misconduct or the presence of other substantial research irregularities is a possibility, the allegations are shared with the corresponding author, who, on behalf of all of the coauthors, is requested to provide a detailed response. After the response is received and evaluated, additional review and involvement of experts (such as statistical reviewers) may be obtained. For cases in which it is unlikely that misconduct has occurred, clarifications, additional analyses, or both, published as letters to the editor, and often including a correction notice and correction to the published article are sufficient.
Institutions are expected to conduct an appropriate and thorough investigation of allegations of scientific misconduct. Ultimately, authors, journals, and institutions have an important obligation to ensure the accuracy of the scientific record. By responding appropriately to concerns about scientific misconduct, and taking necessary actions based on evaluation of these concerns, such as corrections, retractions with replacement, and retractions, CPA will continue to fulfill the responsibilities of ensuring the validity and integrity of the scientific record.
Grievances and Appeals
CPA will have a clear procedure for handling complaints against the journal, Editorial Staff, Editorial Board or Publisher. The complaints will be clarified to the respected person with respect to the case of complaint. The scope of complaints include anything related to the journal business process, i.e. editorial process, found citation manipulation, unfair editor/reviewer, peer-review manipulation, etc. The complaint cases will be processed according to COPE guideline.
Ethical lapse
If the research work involves chemicals, human, animals, procedures or equipment that have any unusual hazards inherent in their use, the author must clearly identify these in the manuscript in order to obey ethical conduct of research using animals and human subjects. If required, Authors must provide legal ethical clearance from the association or legal organization.
If the research involves confidential data and of business/marketing practices, authors should clearly justify this matter whether the data or information will be hidden securely or not